Skip to main content

Δημοσίευση στις 2020 Mar 2 στο PubMed:


Georgios Ntaios 

, Apostolos Tzikas 

, Emmanouil Vavouranakis 

, Dimitrios Nikas 

, Georgios Katsimagklis 

, Eleni Koroboki 

, Antonis S Manolis 

, Haralampos Milionis 

, Konstantinos Papadopoulos 

, Skevos Sideris 
, Konstantinos Spengos 

, Konstantinos Toutouzas 

, Dimitrios Tziakas 

, Sofia Vassilopoulou 

, Ioannis Kanakakis 

, Konstantinos Vemmos 

, Konstantinos Tsioufis 

[Online ahead of print]


Item in Clipboard

Georgios Ntaios et al.

Hellenic J Cardiol.



Patent foramen ovale (PFO) is a frequent echocardiographic finding and can be found in approximately 15-25% of the general population1 (Figure 1). The incidence of PFO is 2- to 3-fold higher in patients with stroke of undetermined etiology compared to the general population, a finding that implies a causative role of PFO in patients with stroke of undetermined etiology 2,3. In this context, percutaneous PFO closure has been increasingly used as a strategy to prevent stroke recurrence in patients with stroke of no apparent cause 4. During the recent years, evidence about the efficacy and safety of this strategy has accumulated through observational studies and well-designed randomized trials5-12.This paper is a consensus statement of expert panelists from the Hellenic Stroke Organization (HSO) and the Working Group for Stroke of the Hellenic Society of Cardiology (HSC) for the secondary prevention in patients with embolic stroke of undetermined source and PFO. It aims to assist clinicians, patients/families and the Hellenic regulatory authorities to design optimal secondary prevention strategies for this patient population. The recommendations of the panelists are summarized in Table 1.


PFO closure; Patent foramen ovale; embolic stroke of undetermined source.

Similar articles